Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company focuses on diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.